Raymond James & Associates Catalyst Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$150 Billion
Q2 2024

A detailed history of Raymond James & Associates transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 48,371 shares of CPRX stock, worth $958,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,371

Previous 56,993 15.13%

Holding current value

$958,713

Previous $908,000 17.51%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$14.68 - $16.92 $126,570 - $145,884	-8,622 Reduced 15.13%	48,371 $749,000
Q1 2024 Apr 22, 2024	BUY	$13.18 - $17.11 $88,490 - $114,876	6,714 Added 13.35%	56,993 $908,000
Q4 2023 Jan 16, 2024	BUY	$11.78 - $17.29 $24,090 - $35,358	2,045 Added 4.24%	50,279 $845,000
Q3 2023 Oct 24, 2023	BUY	$11.69 - $15.02 $5,342 - $6,864	457 Added 0.96%	48,234 $563,000
Q2 2023 Jul 25, 2023	SELL	$11.5 - $18.08 $90,930 - $142,958	-7,907 Reduced 14.2%	47,777 $642,000
Q1 2023 Apr 14, 2023	BUY	$14.34 - $21.05 $191,740 - $281,459	13,371 Added 31.6%	55,684 $923,000
Q4 2022 Feb 08, 2023	BUY	$12.25 - $19.5 $160,634 - $255,703	13,113 Added 44.91%	42,313 $787,000
Q3 2022 Oct 25, 2022	BUY	$7.06 - $15.52 $48,544 - $106,715	6,876 Added 30.8%	29,200 $375,000
Q2 2022 Aug 12, 2022	BUY	$6.23 - $8.57 $139,078 - $191,316	22,324 New	22,324 $156,000
Q1 2021 May 14, 2021	SELL	$3.45 - $4.69 $40,454 - $54,994	-11,726 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$2.97 - $5.08 $17,820 - $30,480	-6,000 Reduced 33.85%	11,726 $35,000
Q2 2020 Jul 28, 2020	SELL	$3.48 - $5.05 $3,480 - $5,050	-1,000 Reduced 5.34%	17,726 $82,000
Q1 2020 Apr 21, 2020	SELL	$2.61 - $5.21 $21,942 - $43,800	-8,407 Reduced 30.98%	18,726 $72,000
Q4 2019 Feb 12, 2020	BUY	$3.67 - $5.7 $15,142 - $23,518	4,126 Added 17.93%	27,133 $102,000
Q3 2019 Nov 07, 2019	BUY	$3.89 - $7.43 $21,395 - $40,865	5,500 Added 31.42%	23,007 $122,000
Q2 2019 Aug 06, 2019	BUY	$2.7 - $6.11 $12,150 - $27,495	4,500 Added 34.6%	17,507 $67,000
Q1 2019 May 06, 2019	SELL	$2.11 - $5.33 $4,220 - $10,660	-2,000 Reduced 13.33%	13,007 $66,000
Q4 2018 Feb 11, 2019	BUY	$1.92 - $3.62 $4,800 - $9,050	2,500 Added 19.99%	15,007 $29,000
Q3 2018 Nov 14, 2018	BUY	$2.81 - $3.78 $35,144 - $47,276	12,507 New	12,507 $47,000

Others Institutions Holding CPRX

# of Institutions

285

Shares Held

96.6M

Call Options Held

29.2K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.04B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Catalyst Pharmaceuticals, Inc. Transaction History